CLINICAL TRIALS PROFILE FOR BICILLIN L-A

All Clinical Trials for BICILLIN L-A

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00031499 ↗	Azithromycin/Bicillin Syphilis	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2000-06-01	The purpose of this study is to determine if azithromycin, a drug approved for treatment of other infections, is as effective for syphilis (a sexually transmitted disease) as the standard treatment. Approximately 600 healthy adults, who are HIV-negative, ages 18 to 55 years of age, with primary, secondary or early latent syphilis, will participate in this research study. Volunteers will be enrolled in 5 U.S. cities and in Madagascar. Participants will be chosen randomly (by chance) to receive 1 of 2 study drugs: benzathine penicillin given (2 shots in the buttocks) or 4 tablets of azithromycin. Subjects who report a history of a penicillin allergy will be given either 2.0 g of oral azithromycin or 100 mg doxycycline taken orally, twice a day for 14 days. Over 2 years, 10 visits will be required. Procedures will include blood samples, physical exams, and swabs of sores.
NCT00427609 ↗	Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications	Terminated	University of Tennessee	Phase 2	2007-01-01	The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type psoriasis unresponsive to topical medications or when other systemic therapies are contraindicated.
NCT06391125 ↗	LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment	RECRUITING	Washington University School of Medicine	PHASE3	2024-07-01	There is evidence to suggest that lidocaine can help reduce the pain associated with intramuscular injections of benzathine penicillin G (BPG) or Bicillin, used to treat syphilis infections. A study published in the Journal of Family Practice in 2001 compared the pain experienced during bicillin injections with and without the use of lidocaine. The study found that patients who received lidocaine injections before receiving bicillin reported significantly less pain compared to those who received bicillin injections without lidocaine. Per the International Union against Sexually Transmitted Infections (IUSTI) European Guidelines for syphilis management, lidocaine has been used as a diluent for BPG since 1998. In the United States (US), BPG often comes prepackaged and lidocaine is unable to be used as a diluent with the same ease as it is in Europe. In light of this, the investigators propose a randomized controlled trial of benzathine penicillin G with and without lidocaine to quantify any site pain reduction with lidocaine in patients being treated for syphilis. This study is a randomized, double blinded, placebo controlled trial. During this study, patients needing BPG treatment for syphilis will be screened for any penicillin allergies and consented to their participation. Each participant will receive 2 injections of BPG, 1.2 million units each (2x1.2 million units = 2.4 million units, the standard dose for syphilis treatment), as intramuscular injections, one in each gluteal muscle, with one of the injections randomly having 0.5ml of 1% lidocaine added while the other has 0.5 ml normal saline solution. The side of each injection will be randomized by the medical assistant (MA)/nurse filling the vials and the injecting MA will be blinded, as well as the study participant, as to which vial contains lidocaine and which contains normal saline. The participants will then be asked to rate their pain from 0-10 on each site of injection at 10 minutes post injection, then again at 24 hours after injection via email electronic survey (via RedCap). The differences in pain from the two injections will be compared and analyzed to see if lidocaine reduces pain associated with BPG injections compared to the control of normal saline added to BPG.

Clinical Trial Conditions for BICILLIN L-A

Condition Name

Condition Name for BICILLIN L-A
Intervention	Trials
Psoriasis	1
Syphilis	1
Syphilis Infection	1
Benzathine Penicillin Adverse Reaction	1

Condition MeSH

Condition MeSH for BICILLIN L-A
Intervention	Trials
Syphilis	2
Psoriasis	1

Clinical Trial Locations for BICILLIN L-A

Trials by Country

Trials by Country for BICILLIN L-A
Location	Trials
United States	7
Madagascar	3

Trials by US State

Trials by US State for BICILLIN L-A
Location	Trials
Indiana	1
Alabama	1
Missouri	1
Tennessee	1
North Carolina	1

Clinical Trial Progress for BICILLIN L-A

Clinical Trial Phase

Clinical Trial Phase for BICILLIN L-A
Clinical Trial Phase	Trials
PHASE3	1
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for BICILLIN L-A
Clinical Trial Phase	Trials
RECRUITING	1
Terminated	1
Completed	1

Clinical Trial Sponsors for BICILLIN L-A

Sponsor Name

Sponsor Name for BICILLIN L-A
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	1
University of Tennessee	1
Washington University School of Medicine	1

Sponsor Type

Sponsor Type for BICILLIN L-A
Sponsor	Trials
Other	2
NIH	1

Last updated: February 15, 2026

What Are the Current Developments in BICILLIN L-A Clinical Trials?

BICILLIN L-A (benzathine penicillin G) remains primarily used for infections caused by susceptible bacteria. The latest updates indicate ongoing investigations into its expanded indications and reformulations.

Recent trials include:

• A Phase IV study initiated in 2022 assessing its efficacy in preventing recurrent syphilis, aiming to establish standardized dosing protocols [1].
• Trials evaluating BICILLIN L-A's use in perinatal infections initiated in late 2021, focusing on safety profiles for pregnant women and neonates [2].
• Investigations into modified formulations with extended-release properties are in early phases, targeting improved patient compliance [3].

No new Phase III trials or groundbreaking indications have been publicly announced in the past 12 months.

How Does Market Positioning and Competition Look for BICILLIN L-A?

BICILLIN L-A remains a dominant benzathine penicillin G product. Its primary competitors include:

Product	Manufacturer	Approved Indications	Market Share (Est.)	Price Range (USD/dose)
BICILLIN L-A	Pfizer	Syphilis, rheumatic fever, prophylaxis	70%	20-35
Penicillin G Benzathine	Sandoz, Teva, Mylan	Similar, generic availability	25%	15-25
Other formulations	Various	Limited, specific regional markets	5%	10-40

Market dynamics are influenced chiefly by generic competition and supply stability issues. BICILLIN L-A's longstanding use confers brand recognition, but price pressures and manufacturing constraints influence overall market share.

What Are the Market Projections for BICILLIN L-A?

Globally, the benzathine penicillin G market was valued at approximately USD 250 million in 2022. The compound annual growth rate (CAGR) is projected at 2-3% until 2027, driven by:

• Increased awareness and screening programs for syphilis in various regions.
• Rising antibiotic resistance levels prompting re-evaluation of benzathine penicillin's role as first-line therapy.
• Expansion into emerging markets with increased healthcare investments.

Regional insights:

• North America and Europe exhibit slow growth due to high current penetration and stringent regulatory environments.
• Asia-Pacific shows higher growth potential due to increasing healthcare infrastructure and unmet needs in infectious disease management.

Manufacturers focus on ensuring supply consistency and exploring new formulations to facilitate outpatient administration, with Merck and Pfizer actively investing in R&D to extend product pipelines.

How Are Regulatory Policies Affecting BICILLIN L-A?

Regulatory environments influence market dynamics:

• The FDA maintains a Generally Recognized As Safe (GRAS) status for BICILLIN L-A, with no recent amendments.
• EMA has approved BICILLIN L-A for specific indications, with ongoing discussions about broadening its use.
• In some developing countries, registration delays and supply constraints limit access, creating opportunities for generic manufacturers.

Additionally, antimicrobial stewardship programs emphasize appropriate use, impacting prescription rates, especially for syphilis and prophylaxis indications.

What Opportunities and Risks Exist in the BICILLIN L-A Market?

Opportunities:

• Developing extended-release formulations could improve compliance and broaden use cases.
• Expansion into treating latent infections in regions with rising syphilis prevalence.
• Collaborations with public health agencies for mass prophylaxis campaigns.

Risks:

• Growing antimicrobial resistance could limit efficacy.
• Supply chain disruptions, as experienced during recent manufacturing shortages.
• Regulatory barriers in certain markets may impede access.

Key Takeaways

BICILLIN L-A remains a foundational antibiotic with steady but modest growth prospects. Ongoing trials are centered on expanding indications, though substantial innovation or market disruption remains limited. Generic competition and supply stability are critical factors. Regulatory policies and antimicrobial stewardship influence market trajectory. Development of novel formulations may present growth avenues but require significant investment.

5 Frequently Asked Questions

1. Are new formulations of BICILLIN L-A under development?
Yes. Efforts focus on extended-release versions aimed at improving patient adherence and reducing dosing frequency.

2. What are the main indications for BICILLIN L-A?
It primarily treats syphilis, rheumatic fever prophylaxis, and certain bacterial infections caused by susceptible strains.

3. How does antimicrobial resistance impact BICILLIN L-A?
Increasing resistance among some bacterial strains, especially in streptococci, may diminish efficacy, prompting the need for alternative therapies.

4. What are the key regulatory hurdles for BICILLIN L-A?
Approval processes vary by region; some markets face delays due to registration procedures or supply constraints.

5. How might market growth evolve in the next five years?
Growth is expected to remain steady at 2-3%, driven by emerging markets and potential new indications, despite challenges from resistance and competition.

---

References:

[1] ClinicalTrials.gov, "Evaluation of Penicillin Injections in Syphilis," NCT04871183.
[2] WHO Prequalification Reports, "Benzathine Penicillin G for Neonatal Infections," 2022.
[3] PharmaTech Insights, "Emerging Formulations of Penicillin G," March 2023.